Search results
Results From The WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Sanofi Pasteur. Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccine.
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [8][9]
September 24, 2024 at 2:17 PM. (Reuters) -Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...
September 3, 2024 at 6:16 PM. Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt ...
Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U ...
Innovative Medicines Canada (IMC) is a national association of pharmaceutical companies that represents the interests of the research-based pharmaceutical industry in Canada. Its membership includes biopharmaceutical companies, vaccine developers, and manufacturers of medical devices, and works with government agencies, insurance companies ...
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Au Sanofi's tolebrutinib drug delays progressive MS by 31% in ...